Pricing Log in Create free account
Saturday 17 October 2026 Export MEDP’s income statement to Excel — free account

Medpace Holdings, Inc.

MEDP Healthcare Diagnostics & Research

Medpace Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.5 billion, up 20.0% from fiscal 2024. In the quarter to June 2026, revenue grew 17.2%, EPS grew 36.4% and free cash flow fell 3.03%, each against the same quarter a year earlier. Revenue growth for ten consecutive years, operating cash flow growth for ten.

618.47 10.13 −1.61%
Market cap
$17.6B
P/E
35.6×
Fwd P/E
26.7×
Dividend yield
—
F-score
8/9
Altman Z
8.04
Beneish M
−2.92
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 439.35
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell 11 2 — — 1 — 1 — 2 12 6 —
Insider Ownership 19.54%

Capital & Financial Ratios $m

Market Cap 17,550.00
Revenue 2,782.29
Net Income 491.50
Free Cash Flow 706.69
Net Debt (502.69)
Current Ratio 0.73 (below 1: weak)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 35.56 (above 35: high)
Fwd P/E 26.70
P/S ratio 6.26
P/B ratio 40.16 (above 6: high)
Past 5Y EPS Growth 31.81% (at or above 15%: strong)
This Y EPS Growth 15.24% (at or above 15%: strong)
Next Y EPS Growth 9.91%
Next Y revenue growth 12.72% (at or above 10%: strong)
Next 5Y EPS Growth 12.05%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 6.1×, against a ten-year median of 4.3×; over the ten years it ranged from 2.7× in 2019 to 7.1× in 2021.
P/E against its own 10 years 62.02%
10-year low 10-year high
P/S against its own 10 years 87.17%
10-year low 10-year high
P/B against its own 10 years 94.49%
10-year low 10-year high
EV/Sales against its own 10 years 88.44%
10-year low 10-year high
EV/FCF against its own 10 years 82.81%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2025 Powerpack
2024 Powerpack
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2017 Powerpack
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 245 669 497 503
Receivables 298 296 402 442
Inventory — — — —
Other — — — —
594 1,029 990 1,050
2023 2024 2025 Q'26
Payables 32 33 28 38
ST’ Debt — — — —
Other 600 764 907 947
925 1,105 1,344 1,435

Compound Annual Growth %

10y 5y 3y
Sales 21.56% 22.27% 20.12%
Cash Flow 23.58% 22.49% 22.49%
Earnings 0.00% 25.50% 22.51%
Book Value 1.05% (10.64%) 5.91%

Revenue $m

Mar Jun Sep Dec Year
’26 707 707 — — —
’25 559 603 660 708 2,530
’24 511 528 533 537 2,109
’23 434 461 492 498 1,886
’22 331 351 384 394 1,460
’21 260 278 296 309 1,142
’20 231 205 230 260 926
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 152 162 — — —
’25 126 149 246 193 713
’24 153 116 149 191 609
’23 80 83 114 156 433
’22 46 97 108 137 388
’21 57 63 72 71 263
’20 49 44 60 105 259
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 145 138 — — —
’25 116 142 235 188 682
’24 147 104 139 183 572
’23 71 74 106 146 397
’22 37 85 101 127 351
’21 51 57 66 62 235
’20 44 35 51 98 227
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 4.28 4.25 — — —
’25 3.67 3.10 3.86 4.67 15.28
’24 3.20 2.75 3.01 3.67 12.63
’23 2.27 1.93 2.22 2.46 8.88
’22 1.69 1.46 2.05 2.12 7.28
’21 1.14 1.06 1.29 1.32 4.81
’20 0.76 0.64 1.09 1.35 3.84
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

2.9
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 26.51 21.76 31.75 48.18 58.72 130.74 126.95 167.00 277.72 250.05

Analyst estimates 2026–2028

Powerpack
High 38.94 39.64 65.09 86.71 150.57 231.00 235.72 317.57 459.77 626.26
People
People Employees 2,500 2,500 2,900 3,500 3,600 4,500 5,200 5,900 5,900 6,200
Revenue/emp, $m 0.17 0.17 0.24 0.25 0.26 0.25 0.28 0.32 0.36 0.41
Income, $m
Income, $m Revenue 422 436 705 861 926 1,142 1,460 1,886 2,109 2,530
Gross margin, % 52.91 51.45 64.19 62.72 61.72 61.39 63.36 66.16 67.66 71.06
EBT 22 57 94 125 169 202 283 336 476 542
EBT margin, % 5.21 13.06 13.33 14.50 18.20 17.67 19.37 17.80 22.57 21.44
Net income 13 39 73 100 145 182 245 283 404 451
Depreciation 61 38 32 23 19 21 22 26 29 28
Per share, $
Per share, $ Revenue 11.81 11.17 19.82 24.00 25.98 31.85 45.08 61.38 68.13 87.72
Earnings 0.38 1.00 2.05 2.79 4.07 5.06 7.57 9.20 13.06 15.64
Cash flow 2.57 2.49 4.41 5.63 7.26 7.34 11.98 14.11 19.67 24.73
Capex (0.38) (0.31) (0.45) (0.50) (0.88) (0.79) (1.14) (1.19) (1.18) (1.09)
Free cash flow 2.19 2.18 3.95 5.13 6.38 6.55 10.84 12.91 18.49 23.64
Book value 17.11 12.89 16.59 20.24 22.61 26.57 11.93 18.19 26.67 15.91
Shares, m 36 39 36 36 36 36 32 31 31 29
Valuation, ×
Valuation, × P/E 90.29 37.14 25.20 30.13 34.20 43.01 27.37 33.22 25.44 35.87
P/S 3.04 3.33 2.67 3.50 5.36 6.83 4.62 4.98 4.88 6.40
P/B 2.10 2.88 3.19 4.15 6.16 8.19 17.46 16.80 12.46 35.29
EV/Sales 3.41 3.83 2.81 3.43 5.13 6.49 4.67 4.91 4.61 6.25
EV/FCF 18.37 19.52 14.08 16.04 20.91 31.55 19.43 23.33 17.00 23.19
Cash, $m
Cash, $m Operating cash flow 92 97 157 202 259 263 388 433 609 713
Capex (14) (12) (16) (18) (31) (28) (37) (37) (37) (31)
Free cash flow 78 85 141 184 227 235 351 397 572 682
Balance, $m
Balance, $m Working capital (35) (63) (79) (26) 34 134 (470) (331) (75) (354)
Total debt 192 248 106 11 16 16 50 — — —
Net debt 155 222 83 (121) (262) (445) 22 (245) (669) (497)
Shareholders’ equity 611 504 590 726 806 953 386 559 826 459
Returns, %
Returns, % ROA 1.37 4.05 7.60 9.49 11.44 11.92 16.29 18.80 21.52 22.13
ROIC 4.29 5.59 9.39 13.14 19.19 24.45 42.68 67.15 178.91 0.00
ROE 2.62 7.02 13.34 15.22 18.92 20.68 36.64 59.83 58.42 70.23
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Medpace Holdings, Inc. vs peers in Diagnostics & Research (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
DGX Quest Diagnostics Incorporated $26.4B 24.6× 20.8× +10.21% (above 0%: growing) +14.74% (above 0%: growing) +5.28% (above 0%: growing) 33.75% 15.08% Compare
LH Labcorp Holdings Inc. $26.4B 26.2× 19.0× +5.78% (above 0%: growing) +28.42% (above 0%: growing) −42.01% (below 0%: shrinking) 29.80% 12.10% Compare
GH Guardant Health, Inc. $22.3B — (loss-making) — (loss-making) +44.33% (above 0%: growing) n/m −5.46% (below 0%: shrinking) 65.39% (38.55%) Compare
MEDP Medpace Holdings, Inc. $17.6B 35.6× 26.7× +17.24% (above 0%: growing) +36.39% (above 0%: growing) −3.03% (below 0%: shrinking) 71.36% 20.76%
RVTY Revvity Inc. $17.3B 72.7× 37.5× +1.31% (above 0%: growing) +2.17% (above 0%: growing) +59.29% (above 0%: growing) 57.13% 12.24% Compare
CRL Charles River Laboratories International, Inc. $14.6B — (loss-making) 29.6× −2.72% (below 0%: shrinking) n/m −12.22% (below 0%: shrinking) 36.19% 11.94% Compare
ICLR ICON PLC $13.5B 254× 23.8× +1.20% (above 0%: growing) −59.31% (below 0%: shrinking) +109.66% (above 0%: growing) 23.23% 6.68% Compare
QGEN QIAGEN N.V. $9.5B 23.6× 17.5× +0.28% (above 0%: growing) +7.94% (above 0%: growing) +30.45% (above 0%: growing) 63.62% 24.75% Compare
TWST Twist Bioscience Corporation $9.5B — (loss-making) — (loss-making) +23.24% (above 0%: growing) n/m −7.23% (below 0%: shrinking) 52.76% (30.65%) Compare
Median of peers $15.9B 26.2× 22.3× +3.54% +7.94% −0.09% 44.48% 12.02%

All 52 Diagnostics & Research stocks →

Medpace Holdings, Inc. (MEDP) key facts

  • Strength: Medpace Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.5 billion, up 20.0% from fiscal 2024.
  • Medpace Holdings, Inc. (MEDP) is a Diagnostics & Research company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, MEDP traded at $618.47, a market capitalization of $17.6 billion.
  • Return on equity was 70.2% and debt-to-equity 0.00.
  • Its Piotroski F-score is 8 out of 9 and its Altman Z-score is 8.04 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Medpace Holdings, Inc. (MEDP) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/MEDP · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com